tiprankstipranks
Vanda Pharmaceuticals (VNDA)
NASDAQ:VNDA
US Market
VNDA
Vanda
RESEARCH TOOLSreports
Want to see VNDA full AI Analyst Report?

Vanda (VNDA) Stock Forecast & Price Target

671 Followers
See the Price Targets and Ratings of:

VNDA Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Vanda
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VNDA Stock 12 Month Forecast

Average Price Target

$19.50
▲(168.23% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Vanda in the last 3 months. The average price target is $19.50 with a high forecast of $21.00 and a low forecast of $18.00. The average price target represents a 168.23% change from the last price of $7.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","22":"$22","7.75":"$7.75","12.5":"$12.5","17.25":"$17.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7.75,12.5,17.25,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,8.076923076923077,9.153846153846153,10.23076923076923,11.307692307692307,12.384615384615383,13.461538461538462,14.538461538461538,15.615384615384615,16.692307692307693,17.769230769230766,18.846153846153847,19.923076923076923,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,7.961538461538462,8.923076923076923,9.884615384615385,10.846153846153847,11.807692307692307,12.76923076923077,13.73076923076923,14.692307692307693,15.653846153846153,16.615384615384613,17.576923076923077,18.53846153846154,{"y":19.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7,7.846153846153846,8.692307692307692,9.538461538461538,10.384615384615385,11.23076923076923,12.076923076923077,12.923076923076923,13.76923076923077,14.615384615384615,15.461538461538462,16.307692307692307,17.153846153846153,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$21.00Average Price Target$19.50Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on VNDA
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$21
Buy
188.86%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Phreesia (PHR), CSPC Pharmaceutical Group (CHJTF)
Truist Financial Analyst forecast on VNDA
Les Sulewski
Truist Financial
Truist Financial
$18
Buy
147.59%
Upside
Reiterated
05/07/26
Truist Financial Sticks to Its Buy Rating for Vanda (VNDA)
B. Riley Securities Analyst forecast on VNDA
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$14→$17
Buy
133.84%
Upside
Reiterated
02/25/26
B. Riley Securities Reaffirms Their Buy Rating on Vanda (VNDA)
Cantor Fitzgerald Analyst forecast on VNDA
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$11
Buy
51.31%
Upside
Reiterated
02/23/26
Analysts Are Bullish on These Healthcare Stocks: Vanda (VNDA), Abeona Therapeutics (ABEO)
Jefferies Analyst forecast on VNDA
Andrew Tsai
Jefferies
Jefferies
$5→$7.5
Hold
3.16%
Upside
Reiterated
12/31/25
Vanda Pharmaceuticals price target raised to $7.50 from $5 at JefferiesVanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on VNDA
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$21
Buy
188.86%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Phreesia (PHR), CSPC Pharmaceutical Group (CHJTF)
Truist Financial Analyst forecast on VNDA
Les Sulewski
Truist Financial
Truist Financial
$18
Buy
147.59%
Upside
Reiterated
05/07/26
Truist Financial Sticks to Its Buy Rating for Vanda (VNDA)
B. Riley Securities Analyst forecast on VNDA
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$14→$17
Buy
133.84%
Upside
Reiterated
02/25/26
B. Riley Securities Reaffirms Their Buy Rating on Vanda (VNDA)
Cantor Fitzgerald Analyst forecast on VNDA
Olivia Brayer
Cantor Fitzgerald
Cantor Fitzgerald
$11
Buy
51.31%
Upside
Reiterated
02/23/26
Analysts Are Bullish on These Healthcare Stocks: Vanda (VNDA), Abeona Therapeutics (ABEO)
Jefferies Analyst forecast on VNDA
Andrew Tsai
Jefferies
Jefferies
$5→$7.5
Hold
3.16%
Upside
Reiterated
12/31/25
Vanda Pharmaceuticals price target raised to $7.50 from $5 at JefferiesVanda Pharmaceuticals price target raised to $7.50 from $5 at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vanda

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
10/17 ratings generated profit
59%
Average Return
+12.84%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +12.84% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
13/17 ratings generated profit
76%
Average Return
+29.24%
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +29.24% per trade.
2 Years
Ram SelvarajuH.C. Wainwright
Success Rate
14/17 ratings generated profit
82%
Average Return
+24.61%
Copying Ram Selvaraju's trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +24.61% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VNDA Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
11
14
10
9
6
Buy
0
1
2
2
2
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
16
12
11
8
In the current month, VNDA has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. VNDA average Analyst price target in the past 3 months is 19.50.
Each month's total comprises the sum of three months' worth of ratings.

VNDA Financial Forecast

VNDA Earnings Forecast

Next quarter’s earnings estimate for VNDA is -$0.60 with a range of -$0.69 to -$0.49. The previous quarter’s EPS was -$0.82. VNDA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VNDA has Performed in-line its overall industry.
Next quarter’s earnings estimate for VNDA is -$0.60 with a range of -$0.69 to -$0.49. The previous quarter’s EPS was -$0.82. VNDA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VNDA has Performed in-line its overall industry.

VNDA Sales Forecast

Next quarter’s sales forecast for VNDA is $61.78M with a range of $60.00M to $63.00M. The previous quarter’s sales results were $51.72M. VNDA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VNDA has Performed in-line its overall industry.
Next quarter’s sales forecast for VNDA is $61.78M with a range of $60.00M to $63.00M. The previous quarter’s sales results were $51.72M. VNDA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VNDA has Performed in-line its overall industry.

VNDA Stock Forecast FAQ

What is VNDA’s average 12-month price target, according to analysts?
Based on analyst ratings, Vanda Pharmaceuticals’s 12-month average price target is 19.50.
    What is VNDA’s upside potential, based on the analysts’ average price target?
    Vanda Pharmaceuticals has 168.23% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VNDA a Buy, Sell or Hold?
          Vanda Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Vanda Pharmaceuticals’s price target?
            The average price target for Vanda Pharmaceuticals is 19.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $21.00 ,the lowest forecast is $18.00. The average price target represents 168.23% Increase from the current price of $7.27.
              What do analysts say about Vanda Pharmaceuticals?
              Vanda Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of VNDA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.